Home > Insider Trading > Filing (0001562180-25-004717)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1517022	Akebia Therapeutics Inc.	AKBA	Pharmaceutical Preparations (2834)	208756903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2007730	C Richard Malabre	C/O Akebia Therapeutics, Inc 245 First St. Cambridge MA 02142	Svp, Chief Accounting Officer	No	No	No	No

Transaction Summary

Sold:	15,000 shares	Avg. Price: $4.01	Total Value: $60,150.00
Number of Shares After Transactions:	266,914 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-06-09	15,000	$1.68	281,914	No	4	M	Direct
Common Stock	Disposition	2025-06-09	15,000	$4.01	266,914	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy)	Disposition	2025-06-09	15,000	$0.00	15,000	$1.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
321,000		2034-01-31	No	4	M	Direct

Footnotes

This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
The shares were sold at prices ranging from $4.00 to $4.03 and the price reported reflects the weighted average sale price.
The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.